Home
Menu
Updates
ARISTO is ranked No. 3 in its Covered market (Source: IQVIA MAT’May’24)ARISTO has launched the World’s No.1 probiotic L. rhamnosus GG as ‘ProGG’ under the technical tie-up with the Innovator Chr. Hansen, DenmarkARISTO continues to be No. 5th company in India as per SMSRC prescription audit data (Nov-Feb’24)ARISTO is ranked No. 4 on CAGR (5 years) among the top 15 companies of the India Pharma Market (Source: IQVIA MAT’May’24)
Aristo-at-a-galance-1
Aristo-at-a-galance-2

ARISTO at a Glance....

CORPORATE IQVIA DATA (CONVERTED IN TO US$)

Revenues ( Rs. In Crs. )
:
5870.38
Market Share
:
3.10%
Gain in Market Share%
:
-0.02
Rx Audit Rank (SMSRC) MAT AUG'24
:
5
Growth
:
7.27%
CAGR (5 years)
:
12.25%
Rank in Indian Pharma Market
:
10
Covered Market Size ( Rs. In Crs.)
:
92281.56
Covered Market Growth%
:
7.44
Market Share in Covered Market
:
6.11%
Rank in Covered Market
:
3
Front Line Sales Force
:
5100

Source : Stockist Secondary Audit IMS - MAT AUG'24 Dataset
US$ = 83.78 - (30/09/2024)

Monocef-O CV DT – 100mg, 62.5mg

MOLECULEBRANDSTRENGTHCOMPOSITIONPACK SIZETHERAPY
Cefpodoxime, Clavulanic AcidMonocef-O CV DT100mg, 62.5mgEach dispersible uncoated tablet contains: Cefpodoxime Proxetil IP equivalent to Cefpodoxime 100mg, Potassium Clavulanate Diluted IP equivalent to Clavulanic Acid 62.5mg6'sAnti-Bacterial Oral

© ARISTO Pharmaceuticals Private Limited | Website Maintenance by Website Maintenance Services